Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Saturday, May 17, 2025
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Eli Lilly (LLY) earnings Q1 2025

May 1, 2025
in News
Reading Time: 3 mins read
A A
Eli Lilly (LLY) earnings Q1 2025
0
SHARES
ShareShareShareShareShare

READ ALSO

CoreWeave pops 60% this week on AI growth momentum, big Nvidia stake

Novogratz’ Galaxy Digital opens trading on the Nasdaq at $23.50

Eli Lilly (LLY) earnings Q1 2025

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal.

The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 per share, down from a previous guidance of $22.50 to $24 per share. Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.

The company maintained its fiscal 2025 sales guidance of $58 billion to $61 billion. Eli Lilly said the guidance reflects President Donald Trump’s existing tariffs as of May 1, but does not include his planned levies on pharmaceuticals imported into the U.S.

In an interview with CNBC, Eli Lilly CEO Dave Ricks said the company and other drugmakers are already announcing investments in U.S. manufacturing, which is one of the Trump administration’s stated goals of the tariffs.

“I think that actually the threat of tariffs is already bringing back critical supply chains into important industries, chips and pharma,” Ricks said. “So do we need to enact [tariffs?] I’m not so sure.”

He added that Eli Lilly wants to see permanent lower tax rates in the U.S., particularly 15% for domestic production. Ricks said lower taxes drove many drugmakers to manufacture in “low-tax islands like Ireland Singapore and in Switzerland, and that can come back if there’s an economic incentive.”

Eli Lilly’s blockbuster diabetes treatment Mounjaro topped expectations for the first quarter, raking in $3.84 billion in revenue. That’s up a whopping 113% from the same period a year ago.

The company’s weight loss drug Zepbound also beat estimates, booking $2.31 billion in sales for the quarter. That more than quadrupled the $517.4 million that the treatment brought in a year ago, when it had just entered the U.S. market.

Analysts expected Mounjaro and Zepbound to generate $3.81 billion and $2.28 billion in sales, respectively, according to estimates from StreetAccount.

Shares of the company fell 5% in premarket trading.

Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $3.34 adjusted vs. $3.02 expected
  • Revenue: $12.73 billion vs. $12.67 billion expected

The company posted first-quarter revenue of $12.73 billion, up 45% from the same period a year ago. 

Sales in the U.S. jumped 49% to $8.49 billion. Eli Lilly said that was driven by a 57% increase in volume – or the number of prescriptions or units sold – for Zepbound and Mounjaro. That was partially offset by lower realized prices of the drugs, the company said.

The pharmaceutical giant booked net income of $2.76 billion, or $3.06 per share, for the first quarter. That compares with net income of $2.24 billion, or $2.48 share, a year earlier. 

Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $3.34 per share for the first quarter.

Demand in the U.S. has still far outpaced supply of Zepbound and Mounjaro over the last year. Both so-called incretin treatments mimic certain gut hormones to tamp down a person’s appetite and regulate their blood sugar.

The popularity of those injectable drugs has forced both Eli Lilly and its rival Novo Nordisk to invest billions to ramp up manufacturing capacity for their treatments.

The efforts appear to be paying off: The Food and Drug Administration in December reaffirmed its decision to declare the U.S. shortage of tirzepatide — the active ingredient in Zepbound and Mounjaro — over. That decision effectively bars many compounding pharmacies from marketing and selling cheaper, unapproved versions of tirzepatide.

This story is developing. Please check back for updates.

Watch CNBC's full interview with Eli Lilly chairman and CEO David Ricks

Credit: Source link

ShareTweetSendSharePin
Previous Post

How one woman pivoted from corporate HR to become a career coach and astrologist

Next Post

LeBron James has touching moment with wife Savannah after Lakers’ season-ending loss

Related Posts

CoreWeave pops 60% this week on AI growth momentum, big Nvidia stake
News

CoreWeave pops 60% this week on AI growth momentum, big Nvidia stake

May 16, 2025
Novogratz’ Galaxy Digital opens trading on the Nasdaq at .50
News

Novogratz’ Galaxy Digital opens trading on the Nasdaq at $23.50

May 16, 2025
Novo Nordisk CEO to step down as competition weighs on share price
News

Novo Nordisk CEO to step down as competition weighs on share price

May 16, 2025
China calls U.S. trade talks ‘good’ as Trump hints at Xi call
News

China calls U.S. trade talks ‘good’ as Trump hints at Xi call

May 16, 2025
Musk’s xAI Grok white genocide posts violated ‘core values’
News

Musk’s xAI Grok white genocide posts violated ‘core values’

May 16, 2025
Tech companies are prioritizing AI products over safety, experts say
News

Tech companies are prioritizing AI products over safety, experts say

May 15, 2025
Next Post
LeBron James has touching moment with wife Savannah after Lakers’ season-ending loss

LeBron James has touching moment with wife Savannah after Lakers’ season-ending loss

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Bill Ackman says ‘time is the friend of the U.S. and the enemy of China’ in trade war

Bill Ackman says ‘time is the friend of the U.S. and the enemy of China’ in trade war

April 26, 2025
Despelote review: A poignant memoir masquerading as a soccer game

Despelote review: A poignant memoir masquerading as a soccer game

May 2, 2025
Trump set to raise millions from crypto and memecoin this month

Trump set to raise millions from crypto and memecoin this month

May 5, 2025
If banks don’t watch what’s coming, they’ll be extinct in ten years

If banks don’t watch what’s coming, they’ll be extinct in ten years

April 30, 2025
The Xbox Spring Sale is live

The Xbox Spring Sale is live

April 17, 2025
The best SSDs for PS5 in 2025

The best SSDs for PS5 in 2025

April 18, 2025
Japan’s trade surplus with the U.S. ballooned to  billion

Japan’s trade surplus with the U.S. ballooned to $63 billion

April 17, 2025

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • New Food and Beverage Product Launches, May 12 – 16
  • Julius Randle has found the answer to his biggest Knicks red flag in Minnesota
  • CoreWeave pops 60% this week on AI growth momentum, big Nvidia stake
  • Why filling the Strategic Petroleum Reserve could be the secret to Trump’s Middle East success

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In